Difference between revisions of "MYH11"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
[unchecked revision][unchecked revision]
Line 51: Line 51:
  
 
'''[http://www.ccga.io/index.php/Acute_Myeloid_Leukemia_(AML)_with_inv(16)(p13.1q22)_or_t(16;16)(p13.1;q22);_CBFB-MYH11 Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11]'''
 
'''[http://www.ccga.io/index.php/Acute_Myeloid_Leukemia_(AML)_with_inv(16)(p13.1q22)_or_t(16;16)(p13.1;q22);_CBFB-MYH11 Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11]'''
 +
 +
'''[http://www.ccga.io/index.php/CBFB CBFB]'''
  
 
==External Links==
 
==External Links==

Revision as of 15:43, 25 July 2018

Primary Author(s)*

Brian Davis PhD

Synonyms

"myosin heavy chain 11", AAT4; FAA4; SMHC; SMMHC

Genomic Location

Cytoband: 16p13.11

Genomic Coordinates:

Put your text here

chr16:15,703,135-15,857,033(GRCh38/hg38)

chr16:15,796,992-15,950,890(GRCh37/hg19)

Cancer Category/Type

Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms

Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

Approximately 5-8% of AML cases have inv(16)(p13.1q22) or t(16;16)(p13.1;q22) [1].

Gene Overview

The MYH11 gene encodes a smooth muscle myosin belonging to the myosin heavy chain family. The gene product is a subunit of a hexameric protein that consists of two heavy chain subunits and two pairs of non-identical light chain subunits. It functions as a major contractile protein, converting chemical energy into mechanical energy through the hydrolysis of ATP. The pericentric inversion of chromosome 16 [inv(16)(p13q22)] produces a protein bearing the first 165 residues from the N terminus of core-binding factor beta and the C-terminal portion of the smooth muscle myosin heavy chain.

Common Alteration Types

inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

Copy Number Loss Copy Number Gain LOH Loss-of-Function Mutation Gain-of-Function Mutation Translocation/Fusion
X

Internal Pages

Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms

Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

CBFB

External Links

Put your text here - Include as applicable links to: 1) Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2) COSMIC, 3) CIViC, 4) St. Jude ProteinPaint, 5) Precision Medicine Knnowledgebase (Weill Cornell), 6) Cancer Index, 7) OncoKB, 8) My Cancer Genome, 9) UniProt, 10) Pfam, 11) GeneCards, 12) GeneReviews, and 13) Any gene-specific databases.

EXAMPLES

MYH11 by Atlas of Genetics and Cytogenetics in Oncology and Haematology - detailed gene information

MYH11 by COSMIC - sequence information, expression, catalogue of mutations

MYH11 by St. Jude ProteinPaint mutational landscape and matched expression data.

MYH11 by Precision Medicine Knowledgebase (Weill Cornell) - manually vetted interpretations of variants and CNVs

MYH11 by Cancer Index - gene, pathway, publication information matched to cancer type

MYH11 by My Cancer Genome - brief gene overview

MYH11 by UniProt - protein and molecular structure and function

MYH11 by Pfam - gene and protein structure and function information

MYH11 by GeneCards - general gene information and summaries

MYH11 by NCBI Gene - general gene information and summaries

References

EXAMPLE Book

1. Arber DA, et al., (2008). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, Editors. IARC Press: Lyon, France, p117-118.

Notes

*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.